In this video, Sean P. Elliott, MD, MS, FACS, discusses the abstract, “Interim results for the ROBUST III trial evaluating the Optilume drug-coated balloon for anterior urethral strictures,” which was presented during the 2021 American Urological Association annual meeting. Elliott is a professor, vice chair of urology, and director of reconstructive urology at the University of Minnesota, Minneapolis.
KIM-1 emerges as biomarker for MRD, atezolizumab benefit in renal cell carcinoma
June 3rd 2024Circulating kidney injury molecule-1 (KIM-1) may be a biomarker for minimal residual disease, disease recurrence, and benefit from adjuvant atezolizumab in patients with renal cell carcinoma at increased risk of recurrence, according to a retrospective analysis of the phase 3 IMmotion010 trial.